Clinical Trial Update: G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating G1T38 in combination with osimertinib for EGFR-mutant non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• G1T38
• Osimertinib (osimertinib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-05-01